BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38441546)

  • 1. GSG2 promotes thyroid cancer via stabilizing AURKB and activating AKT pathway.
    Zhang F; Huang C
    Aging (Albany NY); 2024 Mar; 16(6):5091-5107. PubMed ID: 38441546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSG2 facilitates the progression of human breast cancer through MDM2-mediated ubiquitination of E2F1.
    Tang Y; Dai G; Yang Y; Liu H
    J Transl Med; 2023 Aug; 21(1):523. PubMed ID: 37537694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo.
    Han X; Kuang T; Ren Y; Lu Z; Liao Q; Chen W
    Exp Cell Res; 2019 Dec; 385(1):111605. PubMed ID: 31493385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-binding protein RNPC1 acts as an oncogene in gastric cancer by stabilizing aurora kinase B mRNA.
    Ji CM; Zhang X; Fang W; Meng L; Wei X; Lu C
    Exp Cell Res; 2021 Sep; 406(1):112741. PubMed ID: 34302858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
    Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; Cheng F
    J Transl Med; 2024 Mar; 22(1):295. PubMed ID: 38515112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smad Ubiquitination Regulatory Factor 1 (Smurf1) Promotes Thyroid Cancer Cell Proliferation and Migration via Ubiquitin-Dependent Degradation of Kisspeptin-1.
    Yan C; Su H; Song X; Cao H; Kong L; Cui W
    Cell Physiol Biochem; 2018; 49(5):2047-2059. PubMed ID: 30244247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects and mechanisms of GSG2 in esophageal cancer progression.
    Geng C; Wang Q; Xing PF; Wang M; Tong SD; Zhou JY
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3409-3421. PubMed ID: 35939116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma.
    Zheng T; Zhou Y; Xu X; Qi X; Liu J; Pu Y; Zhang S; Gao X; Luo X; Li M; Wang X; Dong L; Wang Y; Mao C
    J Transl Med; 2022 Jan; 20(1):20. PubMed ID: 34991623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis.
    Pi WS; Cao ZY; Liu JM; Peng AF; Chen WZ; Chen JW; Huang SH; Liu ZL
    Technol Cancer Res Treat; 2018; 18():1533033819853262. PubMed ID: 31122179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
    Yu F; Lin Y; Xu X; Liu W; Tang D; Zhou X; Wang G; Zheng Y; Xie A
    Int J Oncol; 2020 Jul; 57(1):139-150. PubMed ID: 32319597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AURKB promotes gastric cancer progression via activation of
    Nie M; Wang Y; Yu Z; Li X; Deng Y; Wang Y; Yang D; Li Q; Zeng X; Ju J; Liu M; Zhao Q
    Aging (Albany NY); 2020 Jan; 12(2):1304-1321. PubMed ID: 31982864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of GSG2 inhibits the development and progression of non-small cell lung cancer
    Zhang F; Qiu B; Ji Y; Zhang H; Song P; Sun N; Zhao L; Lv F; Yin L; Gao Y; Xue Q; Gao S; He J
    Cell Cycle; 2023 Jan; 22(2):153-164. PubMed ID: 35972887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer.
    Huang Y; Liu Y; Zhu K; Ma X; Lu R; Zhang M
    Cancer Manag Res; 2021; 13():499-508. PubMed ID: 33500663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
    Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of
    Yu W; Liu W; Feng Y; Zhu C
    Genet Test Mol Biomarkers; 2022 Jan; 26(1):26-36. PubMed ID: 35089075
    [No Abstract]   [Full Text] [Related]  

  • 16. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
    Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
    Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
    Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
    J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.
    Fan X; Wang Y; Fan J; Chen R
    J Cell Biochem; 2019 Jun; 120(6):10643-10651. PubMed ID: 30672020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
    Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
    J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
    Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.